Therapeutic efficacy of177Lu-CHX-A″-DTPA-hu3SI93 radioimmunotherapy in prostate cancer Is enhanced by EGFR inhibition or docetaxel chemotherapy

Prostate

Volumn 69, Issue 1, 2009, Pages 92-104

  Kelly, Marcus P ^a   Lee, Sze Ting ^a   Lee, F T ^a   Smyth, Fiona E ^a   Davis, Ian D ^a   Brechbiel, Martin W ^b   Scott, Andrew M ^a  

^a AUSTIN HOSPITAL   (Australia)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Combined modality; Hu3S193; Prostate cancer; Radioimmunotherapy

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; C FUNCTIONALIZED TRANS CYCLOHEXYLDIETHYLENETRIAMINEPENTAACETIC ACID; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LUTETIUM 177; LUTETIUM 177 PLUS MONOCLONAL ANTIBODY HU3SI93; MONOCLONAL ANTIBODY; PENTETIC ACID DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ENZYME INHIBITOR; ISOTHIOCYANIC ACID DERIVATIVE; LUTETIUM; MONOCLONAL ANTIBODY HU3S193; N (2 AMINO 3 (4 ISOTHIOCYANATOPHENYL)PROPYL)CYCLOHEXANE 1,2 DIAMINE N,N',N',N'',N'' PENTAACETIC ACID; N-(2-AMINO-3-(4-ISOTHIOCYANATOPHENYL)PROPYL)CYCLOHEXANE-1,2-DIAMINE-N,N',N',N'',N''-PENTAACETIC ACID; PENTETIC ACID; RADIOISOTOPE; RADIOSENSITIZING AGENT; TAXOID; TYRPHOSTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIOIMMUNOTHERAPY; REPEATED DRUG DOSE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; PHOSPHORYLATION; PROSTATE TUMOR; RADIATION EXPOSURE; RADIATION RESPONSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENZYME INHIBITORS; HUMANS; ISOTHIOCYANATES; LUTETIUM; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PENTETIC ACID; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS; TYRPHOSTINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58149334926     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20856     Document Type: Article

References (50)

1. Scott AM, Welt S. Antibody-based immunological therapies. Curr Opin Immunol 1997;9(5):717-722.
2. 131I- huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res 2005;11(13):4818-4826.
3. Bethge WA, Sandmaier BM. Targeted cancer therapy and immunosuppression using radiolabeled monoclonal antibodies. Semin Oncol 2004;31(1):68-82.
4. Smith-Jones PM. Radioimmunotherapy of prostate cancer. Q J Nucl Med Mol Imaging 2004;48(4):297-304.
5. Scott AM. Radioimmunotherapy of prostate cancer: Does tumor size matter? J Clin Oncol 2005;23(21):4567-4569.
6. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004;22(13):2522-2531.
7. 177Lu-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23(21):4591-4601.
8. Jhanwar YS, Divgi C. Current status of therapy of solid tumors. J Nucl Med 2005;46 (Suppl 1):141S-150S.
9. Stein R, Govindan SV, Chen S, Reed L, Richel H, Griffiths GL, Hansen HJ, Goldenberg DM. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: Evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I. J Nucl Med 2001;42(6):967-974.
10. Divgi C. Editorial: What ails solid tumor radioimmunotherapy? Cancer Biother Radiopharm 2006;21(2):81.
11. Wu AM, Senter PD. Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23(9):1137-1146.
12. Chinnaiyan P, Allen GW, Harari PM. Radiation and new molecular agents, part II: Targeting HDAC, HSP90, IGF-1R, PI3K, and Ras. Semin Radiat Oncol 2006;16(1):59-64.
13. Ma BB, Bristow RG, Kim J, Siu LL. Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol 2003;21(14):2760-2776.
14. Yacoub A, McKinstry R, Hinman D, Chung T, Dent P, Hagan MP. Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 2003;159(4):439-452.
15. Hagan M, Yacoub A, Dent P. Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carinoma. Clin Cancer Res 2004; 10(17):5724-5731.
16. Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z, Skrinos E, Murone C, Saunder TH, Chappell B, Papenfuss AT, Poon AM, Hopkins W, Smyth FE, MacGregor D, Cher LM, Jungbluth AA, Ritter G, Brechbiel MW, Murphy R, Burgess AW, Hoffman EW, Johns TG, Old LJ. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA 2007;104(10):4071-4076.
17. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33(4):369-385.
18. Baselga J, Arribas J. Treating cancer's kinase 'addiction'. 2004; 10(8):786-787.
19. She Y, Lee F, Chen J, Haimovitz-Friedman A, Miller VA, Rusch VR, Kris MG, Sirotnak FM. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Cln Cancer Res 2003; 9(10 Pt 1):3773-3778.
20. Choy H. Combining taxanes with radiation for solid tumors. Int J Cancer 2000;90(3):113-127.
21. Burke PA, DeNardo SJ, Miers LA, Kukis DL, DeNardo GL. Combined modality radioimmunotherapy. Promise and peril. Cancer 2002;94 (4 Suppl):1320-1331.
22. Kumar P. A new paradigm for the treatment of high-risk prostate cancer: Radiosensitization with docetaxel. Rev Urol 2003;5 (Suppl 3):S71 -77.
23. 90Y-DOTA-peptide-ChL6. Prostate 2002;50(1):27-37.
24. Zhang AL, Russell PJ, Knittel T, Milross C. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway. Prostate 2007;67(15):1630-1640.
25. Boghaert ER, Sridharan L, Armellino DC, Khandke KM, DiJoseph JF, Kunz A, Dougher MM, Jiang F, Kalyandrug LB, Hamann PR, Frost P, Damle NK. Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xeno-grafts. Clin Cancer Res 2004;10(13):4538-4549.
26. Myers RB, Srivastava S, Grizzle WE. Lewis Y antigen as detected by the monoclonal antibody BR96 is expressed strongly in prostatic adenocarcinoma. J Urol 1995;153(5):1572-1574.
27. Martensson S, Bigler SA, Brown M, Lange PH, Brawer MK, Hakomori S. Sialyl-Lewis(x) and related carbohydrate antigens in the prostate. Hum Pathol 1995;26(7):735-739.
28. 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model. J Nucl Med 2006;47(4):716-725.
29. 90Y-CHX-A″-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. Clin Cancer Res 2005;11(19 Pt 2):7080s-7086s.
30. Wong JYC. Systemic targeted radionuclide therapy: Potential new areas. Int J Radiat Oncol Biol Phys 2006;66 (2 Suppl 1):S74-S82.
31. Scott AM, Geleick D, Rubira M, Clarke K, Nice EC, Smyth FE, Stockert E, Richards EC, Carr FJ, Harris WJ, Armour KL, Rood J, Kypridis A, Kronina V, Murphy R, Lee FT, Liu Z, Kitamura K, Ritter G, Laughton K, Hoffman E, Burgess AW, Old LJ. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for tageted immunotherapy of solid tumors. Cancer Res 2000;60(12):3254-3261.
32. Scott AM, Lee F-T, Jones R, Hopkins W, MacGregor D, Cebon JS, Hannah A, Chong G, Paul U, Papenfuss A, Rigopoulos A, Sturrock S, Murphy R, Wirth V, Murone C, Smyth FE, Knight S, Welt S, Ritter G, Richards E, Nice EC, Burgess AW, Old LJ. A Phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: Biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res 2005;11(13): 4810-4817.
33. Wu C, Kobayashi H, Sun B, Yoo TM, Paik CH, Gansow OA, Carrasquillo JA, Pastan I, Brechbiel MW. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. Bioorg Med Chem 1997;5(10): 1925-1934.
34. Nikula TK, Curcio MJ, Brechbiel MW, Gansow OA, Finn RD, Scheinberg DA. A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nucl Med Biol 1995;22(3):387-390.
35. Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice. Cancer Res 2000;60(17):4804-4811.
36. Johns TG, Luwor RB, Murone C, Walker F, Weinstock J, Vitali AA, Perera RM, Jungbluth AA, Stockert E, Old LJ, Nice EC, Burgess AW, Scott AM. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc Natl Acad Sci USA 2003; 100(26):15871-15876.
37. Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, Scott AM, Johns TG. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 2005; 11(17):6390-6399.
38. Behr TM, Liersch T, Greiner-Bechert L, Griesinger F, Behe M, Markus PM, Gratz S, Angerstein C, Brittinger G, Becker H, Goldenberg DM, Becker W. Radioimmunotherapy of small volume disease of metastatic colorectal cancer. Cancer 2002;94 (4 Suppl):1373-1381.
39. Schott ME, Schlom J, Siler K, Milenic DE, Eggensperger D, Colcher D, Cheng R, Kruper WJ Jr, Fordyce W, Goeckeler W. Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates. Cancer 1994; 73 (3 Suppl):993-998.
40. Friesen C, Lubatschofski A, Kotzerke J, Buchmann I, Reske SN, Debatin KM. Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells. Eur J Nucl Med Mol Imaging 2003;30(9):1251-1261.
41. y) in small cell lung cancer with a humanized monoclonal antibody, huS193: A pilot trial testing two dose levels. J Thorac Oncol 2007;2(10):947-952.
42. Scott AM, Tebbutt N, Lee F-T, Cavicchiolo T, Liu Z, Gill S, Poon AMT, Hopkins W, Smyth FE, Murone C, MacGregor D, Papenfuss AT, Chappell B, Saunder TH, Brechbiel MW, Davis ID, Murphy R, Chong G, Hoffman EW, Old LJ. A Phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin Cancer Res 2007; 13(11):3286-3292.
43. 177Lu-labeled immunoconjugate. Cancer Res 1991;51(11):2889-2896.
44. van Gog FB, Brakenhoff RH, Stigter-van Walsum M, Snow GB, van Dongen GA. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer. Int J Cancer 1998;77(1):13-18.
45. Gligorov J, Lotz JP. Preclinical pharmacology of the taxanes: Implications of the differences. Oncologist 2004;9 (Suppl 2):3-8.
46. Stromberg JS, Lee YJ, Armour EP, Martinez AA, Corry PM. Lack of radiosensitization after paclitaxel treatment of three human carcinoma cell lines. Cancer 1995;75(9):2262-2268.
47. Dunne AL, Mothersill C, Robson T, Wilson GD, Hirst DG. Radiosensitization of colon cancer cell lines by docetaxel: Mechanisms of action. Oncol Res 2004;14(9):447-454.
48. Ganansia-Leymarie V, Bischoff P, Bergerat JP, Holl V. Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anticancer Agents 2003;3(4):291-306.
49. Richman CM, DeNardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, Tuscano JM, Wun T, Chew HK, Lara PN, Kukis DL, Natarajan A, Meares CF, Lamborn KR, DeNardo GL. High dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res 2005; 11(16):5920-5927.
50. Meredith RF, Alvarez RD, Partridge EE, Khazaeli MB, Lin C-Y, Macey DJ, Austin JM, Kilgore LC, Grizzle WE, Schlom J, LoBuglio AF. Intraperitoneal radioimmunochemotherapy of ovarian cancer: A Phase I Study. Cancer Biother Radiopharm 2001;16(4):305-315.